Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gabriela Olivia Regalado Porras"'
Autor:
Raquel Gerson Cwilich, Alejandro Zentella Dehesa, Héctor Murrieta González, Laura Daniela Campos Alvarado, Eric Alejandro García López, Christian Patricio Camacho Limas, Gabriela Olivia Regalado Porras, Jesús Miguel Lázaro León, Guillermo Manuel Olivares Beltrán, Juan Alberto Serrano Olvera, Alberto Villalobos Prieto, Diana Alejandra Villegas Osorno, Daniela Shveid Gerson, Alejandro Noguez Ramos
Publikováno v:
Anales Médicos de la Asociación Médica del Centro Médico ABC. 66:238-248
Autor:
Alejandro Noguez Ramos, Guillermo Manuel Olivares Beltrán, Fernando Pérez Zincer, Gabriela Olivia Regalado Porras, Raquel Gerson Cwilich, Yazmin Carolina Blanco Vázquez, Daniela Shveid Gerson, Daniela Vazquez Juarez, Juan Alberto Serrano Olvera, Christian Patricio Camacho Limas, Alberto Villalobos Prieto, Benigno Emmanuel Rodriguez Soto, Álvaro Aguayo González, Ivonne Salcedo Sullk, Samuel Rivera Rivera, Lorena López Zepeda
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:BPI20-022
Autor:
Benigno Rodriguez, Efrain Isaias Camarin Sanchez, Alberto Villalobos, Diana Alejandra Villegas Osorno, Omar Serrano Villamayor, Daniela Shveid Gerson, Gabriela Olivia Regalado Porras, Raquel Gerson, Lorena López Zepeda, Guillermo Olivares, Ervin Saúl Enciso López, José Fabián Martínez-Herrera
Publikováno v:
Journal of Clinical Oncology. 39:e16105-e16105
e16105 Background: Gastric cancer (GC) and gastroesophageal junction cancer (GEJ) are the second most prevalent and lethal digestive malignancies worldwide. According to GLOBOCAN 2020, the incidence in Mexican population is 4.5% and represents 7% of
Autor:
Raul Alejandro Andrade Moreno, Omar Serrano Villamayor, Benigno Rodriguez, Alberto Villalobos, Daniela Shveid Gerson, José Fabián Martínez-Herrera, Ervin Saúl Enciso López, Guillermo Olivares, Gabriela Olivia Regalado Porras, Raquel Gerson Cwilich, Efrain Isaias Camarin Sanchez, Geovani Amador, Diana Alejandra Villegas Osorno, Lorena López Zepeda
Publikováno v:
Journal of Clinical Oncology. 39:e15592-e15592
e15592 Background: Colorectal cancer (CRC) is the most common gastrointestinal neoplasia, with 1.36 million cases worldwide, representing the third cause of death due to cancer. Commonly affects people after the 6th decade of life, but recently the d
Autor:
Christian Patricio Camacho Limas, Fernando Perez-Zincer, Daniela Vazquez Juarez, Samuel Rivera Rivera, Yazmin Carolina Blanco Vázquez, Juan Alberto Serrano, Benigno Rodriguez, Alejandro Noguez-Ramos, Alberto Villalobos, Guillermo Olivares, Angel Azael Lopez Galindo, Lorena López Zepeda, Gabriela Olivia Regalado Porras, Raquel Gerson, José Fabián Martínez-Herrera, Alvaro Aguayo, Cesar Gonzalez De Leon, Daniela Shveid Gerson, Ivonne Salcedo
Publikováno v:
Journal of Clinical Oncology. 38:e13053-e13053
e13053 Background: Breast cancer was the second most common malignant tumor diagnosed in 2018 worldwide, and the main cause of cancer death in women. In Mexico is the leading cause of cancer deaths, the most common molecular subtypes is HR+/HER2- (63
In recent years, the treatment of locally-advanced and metastatic cervical cancer has improved greatly due to the introduction of targeted therapies, new chemotherapy combinations, and emerging treatments. Candidates for potentially curative treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3723ea92ba5f9493b23481df1baef14
https://europepmc.org/articles/PMC6277350/
https://europepmc.org/articles/PMC6277350/
Autor:
Ivonne Salcedo, Jorge Alatorre Alexander, Samuel Rivera Rivera, Juan Alberto Serrano, J. Fabian Martinez Herrera, Alberto Villalobos, Victoria Imaz, Guillermo Olivares, Elina Alexandra Rodriguez Melendez, Christian Patricio Camacho Limas, Fernando Perez-Zincer, Gabriela Olivia Regalado Porras, Alvaro Aguayo, Jesús Miguel Lázaro León, Raquel Gerson
Publikováno v:
Journal of Clinical Oncology. 37:e14090-e14090
e14090 Background: Since 2010, immune checkpoint inhibitors (ICI) have been approved for the treatment of several neoplasms. Their immune-mediated toxicity profile, used as monotherapy (nivolumab [N], Ipilimumab [Ip], pembrolizumab [P]) or in combina